Skip to main content

Advertisement

SpringerLink
Log in

Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies

  • Review Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

In human immunodeficiency virus (HIV)-infected patients, Pneumocystis jirovecii pneumonia (PCP) is a well-known opportunistic infection, and its management has been established. However, PCP is an emerging threat to immunocompromised patients without HIV infection, such as those receiving novel immunosuppressive therapeutics for malignancy, organ transplantation, or connective tissue diseases. Clinical manifestations of PCP are quite different between patients with and without HIV infections. In patients without HIV infection, PCP rapidly progresses, is difficult to diagnose correctly, and causes severe respiratory failure with a poor prognosis. High-resolution computed tomography findings are different between PCP patients with HIV infection and those without. These differences in clinical and radiologic features are the result of severe or dysregulated inflammatory responses that are evoked by a relatively small number of Pneumocystis organisms in patients without HIV infection. In recent years, the usefulness of PCR and serum β-d-glucan assay for rapid and noninvasive diagnosis of PCP has been revealed. Although corticosteroid adjunctive to anti-Pneumocystis agents has been shown to be beneficial in some populations, the optimal dose and duration remain to be determined. Recent investigations revealed that Pneumocystis colonization is prevalent, and that asymptomatic carriers are at risk for developing PCP and can serve as the reservoir for the spread of Pneumocystis by person-to-person transmission. These findings suggest the need for chemoprophylaxis in immunocompromised patients without HIV infection, although its indication and duration are still controversial. Because a variety of novel immunosuppressive therapeutics have been emerging in medical practice, further innovations in the diagnosis and treatment of PCP are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009;301:2578–85.

    Article  PubMed  CAS  Google Scholar 

  2. Thomas CF, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487–98.

    Article  PubMed  CAS  Google Scholar 

  3. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007;5:298–308.

    Article  PubMed  CAS  Google Scholar 

  4. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am. 2010;24:107–38.

    Article  PubMed  Google Scholar 

  5. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis. 2011;24:534–44.

    Article  PubMed  CAS  Google Scholar 

  6. Beck JM, Cushion MT. Pneumocystis workshop: 10th anniversary summary. Eukaryot Cell. 2009;8:446–60.

    Article  PubMed  CAS  Google Scholar 

  7. Huang L, Morris A, Limper AH, Beck JM. An official ATS workshop summary: recent advances and future directions in Pneumocystis pneumonia. Proc Am Thorac Soc. 2006;3:655–64.

    Article  PubMed  Google Scholar 

  8. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis. 2011;5:41–59.

    Article  PubMed  CAS  Google Scholar 

  9. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663–71.

    PubMed  CAS  Google Scholar 

  10. Calderón EJ, Gutiérrez-Rivero S, Durand-Joly I, Dei-Cas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther. 2010;8:683–701.

    Article  PubMed  Google Scholar 

  11. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140:1204–9.

    Article  PubMed  CAS  Google Scholar 

  12. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome. Mayo Clin Proc. 1996;71:5–13.

    Article  PubMed  CAS  Google Scholar 

  13. Roblot F, Godet C, Le Moal G, Garo B. Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002;21:523–31.

    Article  PubMed  CAS  Google Scholar 

  14. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6:644–52.

    Article  PubMed  Google Scholar 

  15. FDA arthritis advisory committee. Safety update on TNF-α antagonists: infliximab and etanercept. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf. (online).

  16. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;8:891.

    Article  PubMed  Google Scholar 

  17. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61:35–41.

    PubMed  CAS  Google Scholar 

  18. Peglow SL, Smulian AG, Linke MJ, Pogue CL, Nurre S, Crisler J, et al. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis. 1990;161:296–306.

    Article  PubMed  CAS  Google Scholar 

  19. Huang L, Crothers K, Morris A, Groner G, Fox M, Turner JR, et al. Pneumocystis colonization in HIV-infected patients. J Eukaryot Microbiol. 2003;50(Suppl):616–7.

    Article  PubMed  Google Scholar 

  20. Nevez G, Raccurt C, Jounieaux V, Dei-Cas E, Mazars E. Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS. 1999;13:535–6.

    Article  PubMed  CAS  Google Scholar 

  21. Medrano FJ, Montes-Cano M, Conde M, de la Horra C, Respaldiza N, Calderon EJ, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis. 2005;11:245–50.

    Article  PubMed  Google Scholar 

  22. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation. 2009;88:380–5.

    Article  PubMed  Google Scholar 

  23. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis. 2008;197:10–7.

    Article  PubMed  CAS  Google Scholar 

  24. Mekinian A, Durand-Joly I, Hatron PY, Moranne O, Denis G, Queyrel V. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology. 2011;50:569–77.

    Article  PubMed  Google Scholar 

  25. Wissmann G, Morilla R, Martín-Garrido I, Friaza V, Respaldiza N, Calderón EJ, et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Invest. 2011;41:343–8.

    Article  PubMed  CAS  Google Scholar 

  26. Durand-Joly I, Soula F, Chabé M, Dalle JH, Lafitte JJ, Dei-Cas E, et al. Long-term colonization with Pneumocystis jirovecii in hospital staffs: a challenge to prevent nosocomial pneumocystosis. J Eukaryot Microbiol. 2003;50(Suppl):614–45.

    Article  PubMed  Google Scholar 

  27. Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis. 2010;50:347–53.

    Article  PubMed  Google Scholar 

  28. Manoloff ES, Francioli P, Taffé P, Van Melle G, Bille J, Hauser PM. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis. 2003;9:132–4.

    Article  PubMed  Google Scholar 

  29. Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun. 1993;61:5406–9.

    PubMed  CAS  Google Scholar 

  30. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect. 2002;4:95–103.

    Article  PubMed  Google Scholar 

  31. Helweg-Larsen J, Lee CH, Jin S, Hsueh JY, Benfield TL, Hansen J, et al. Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f.sp. hominis. AIDS. 2001;15:451–9.

    Article  PubMed  CAS  Google Scholar 

  32. Keely SP, Stringer JR. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol. 1997;35:2745–7.

    PubMed  CAS  Google Scholar 

  33. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol. 2009;36:1600–5.

    Article  PubMed  CAS  Google Scholar 

  34. Gigliotti F, Wright TW. Immunopathogenesis of Pneumosystis carinii pneumonia. Expert Rev Mol Med. 2005;7:1–16.

    Article  PubMed  Google Scholar 

  35. Kelly MN, Shellito JE. Current understanding of Pneumocystis immunology. Future Microbiol. 2010;5:43–65.

    Article  PubMed  CAS  Google Scholar 

  36. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest. 1997;99:2110–7.

    Article  PubMed  CAS  Google Scholar 

  37. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol. 2000;164:3755–63.

    PubMed  CAS  Google Scholar 

  38. Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AB, Lundgren JD. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1995;151:1058–62.

    PubMed  CAS  Google Scholar 

  39. Tasaka S, Kobayashi S, Kamata H, Kimizuka Y, Fujiwara H, Funatsu Y, et al. Cytokine profiles of bronchoalveolar lavage fluid in patients with Pneumocystis pneumonia. Microbiol Immunol. 2010;54:425–33.

    PubMed  CAS  Google Scholar 

  40. Roths JB, Marshall JD, Allen RD, Carlson GA, Sidman CL. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am J Pathol. 1990;136:1173–86.

    PubMed  CAS  Google Scholar 

  41. Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M, et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology. 2010;15:126–31.

    Article  PubMed  Google Scholar 

  42. Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006;25:382–8.

    Article  PubMed  CAS  Google Scholar 

  43. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA. 1992;267:832–7.

    Article  PubMed  CAS  Google Scholar 

  44. Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Azoulay E, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305–10.

    Article  PubMed  Google Scholar 

  45. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187–98.

    Article  PubMed  CAS  Google Scholar 

  46. Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest. 2009;39:1098–109.

    Article  PubMed  CAS  Google Scholar 

  47. Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008;6:122–74.

    PubMed  Google Scholar 

  48. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052–9.

    Article  PubMed  CAS  Google Scholar 

  49. Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, et al. Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res. 2005;25:651–5.

    PubMed  Google Scholar 

  50. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med. 1995;155:1125–8.

    Article  PubMed  CAS  Google Scholar 

  51. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis. 2007;44:1143–9.

    Article  PubMed  Google Scholar 

  52. Schmoldt S, Schuhegger R, Wendler T, Huber I, Söllner H, Hogardt M, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008;46:966–71.

    Article  PubMed  CAS  Google Scholar 

  53. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case–control study. Transpl Infect Dis. 2003;5:84–93.

    Article  PubMed  CAS  Google Scholar 

  54. De Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case–control study. Clin Microbiol Infect. 2010;16:1375–7.

    Article  PubMed  Google Scholar 

  55. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener’s granulomatosis. Am J Respir Crit Care Med. 1995;151:795–9.

    PubMed  CAS  Google Scholar 

  56. Godeau B, Mainardi JL, Roudot-Thoraval F, Hachulla E, Guillevin L, Du Huong LT, et al. Factors associated with Pneumocystis carinii pneumonia in Wegener’s granulomatosis. Ann Rheum Dis. 1995;54:991–4.

    Article  PubMed  CAS  Google Scholar 

  57. Tasaka S, Hasegawa N, Yamada W, Saito F, Nishimura T, Ishizaka A. Clinical features of Pneumocystis pneumonia in patients with systemic lupus erythematosus. Nihon Kokyuki Gakkai Zasshi 2006;44:613–619 (in Japanese).

    Google Scholar 

  58. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246–51.

    PubMed  CAS  Google Scholar 

  59. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780–9.

    Article  PubMed  CAS  Google Scholar 

  60. Bachelez H, Schremmer B, Cadranel J, Mouly F, Sarfati C, Agbalika F, et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med. 1997;157:1501–3.

    Article  PubMed  CAS  Google Scholar 

  61. Phair J, Munõz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161–5.

    Article  PubMed  CAS  Google Scholar 

  62. Wollner A, Mohle-Boetani J, Lambert RE, Perruquet JL, Raffin TA, McGuire JL. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis. Thorax. 1991;46:205–7.

    Article  PubMed  CAS  Google Scholar 

  63. Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome. A multicenter study. Intern Med. 2008;47:915–23.

    Article  PubMed  Google Scholar 

  64. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.

    Article  PubMed  CAS  Google Scholar 

  65. Louie GH, Wang Z, Ward MM. Trends in hospitalizations for Pneumocystis jiroveci pneumonia among patients with rheumatoid arthritis in the US: 1996–2007. Arthritis Rheum. 2010;62:3826–7.

    Article  PubMed  Google Scholar 

  66. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305–12.

    Article  PubMed  CAS  Google Scholar 

  67. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;6:898–906.

    Article  CAS  Google Scholar 

  68. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Goto H, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med. 2011;50:305–13.

    Article  PubMed  CAS  Google Scholar 

  69. Escher M, Stange EF, Herrlinger KR. Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis—a need for prophylaxis. J Crohns Colitis. 2010;4:606–9.

    Article  PubMed  CAS  Google Scholar 

  70. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481–4.

    Article  PubMed  CAS  Google Scholar 

  71. Itaba S, Iwasa T, Sadamoto Y, Nasu T, Misawa T, Inoue K, et al. Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn’s disease. Dig Dis Sci. 2007;52:1438–41.

    Article  PubMed  Google Scholar 

  72. Flori P, Bellete B, Durand F, Raberin H, Cazorla C, Hafid J, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jiroveci pneumonia from bronchoalveolar lavage specimens. J Med Microbiol. 2004;53:603–7.

    Article  PubMed  CAS  Google Scholar 

  73. Caliendo AM, Hewitt PL, Allega JM, Keen A, Ruoff KL, Ferraro MJ. Performance of a PCR assay for detection of Pneumocystis carinii from respiratory specimens. J Clin Microbiol. 1998;36:979–82.

    PubMed  CAS  Google Scholar 

  74. Alvarez-Martínez MJ, Miró JM, Valls ME, Moreno A, Rivas PV, Solé M, et al. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis. 2006;56:153–60.

    Article  PubMed  CAS  Google Scholar 

  75. Ribes JA, Limper AH, Espy MJ, Smith TF. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol. 1997;35:830–5.

    PubMed  CAS  Google Scholar 

  76. Wakefield AE, Guiver L, Miller RF, Hopkin JM. DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia. Lancet. 1991;337:1378–9.

    Article  PubMed  CAS  Google Scholar 

  77. Maskell NA, Waine DJ, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax. 2003;58:594–7.

    Article  PubMed  CAS  Google Scholar 

  78. Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing Pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2009;135:655–61.

    Article  PubMed  CAS  Google Scholar 

  79. Huggett JF, Taylor MS, Kocjan G, Evans HE, Morris-Jones S, Gant V, et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax. 2008;63:154–9.

    Article  PubMed  CAS  Google Scholar 

  80. Fujisawa T, Suda T, Matsuda H, Inui N, Nakamura Y, Sato J, et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology. 2009;14:203–9.

    Article  PubMed  Google Scholar 

  81. Matsumura Y, Ito Y, Iinuma Y, Yasuma K, Yamamoto M, Matsushima A, et al. Quantitative real-time PCR and the (1 → 3)-β-d-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect. 2012;18:591–7.

    Article  PubMed  CAS  Google Scholar 

  82. Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1 → 3)-β-d-glucan assay for the diagnosis of invasive fungal infections: a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46:1864–70.

    Article  PubMed  CAS  Google Scholar 

  83. Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto K, Kawano S, et al. Diagnostic accuracy of serum 1,3-β-d-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7–15.

    Article  PubMed  CAS  Google Scholar 

  84. Marty FM, Koo S, Bryar J, Baden LR. (1 → 3) Beta-d-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med. 2007;147:70–2.

    PubMed  Google Scholar 

  85. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest. 2007;131:1173–80.

    Article  PubMed  CAS  Google Scholar 

  86. Watanabe T, Yasuoka A, Tanuma J, et al. Serum (1 → 3) beta-d-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49:1128–31.

    Article  PubMed  CAS  Google Scholar 

  87. de Boer MG, Gelinck LB, van Zelst BD, van de Sande WW, Willems LN, van Dissel JT, et al. β-d-Glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect. 2011;62:93–100.

    Article  PubMed  Google Scholar 

  88. Koga M, Koibuchi T, Kikuchi T, Nakamura H, Miura T, Iwamoto A, et al. Kinetics of serum β-d-glucan after Pneumocystis pneumonia treatment in patients with AIDS. Intern Med. 2011;50:1397–401.

    Article  PubMed  CAS  Google Scholar 

  89. Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest. 1995;108:415–8.

    Article  PubMed  CAS  Google Scholar 

  90. Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr, Merali S. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia. Lancet. 2003;361:1267–8.

    Article  PubMed  CAS  Google Scholar 

  91. Kuhlman JE, Kavuru M, Fishman EK, Siegelman SS. Pneumocystis carinii pneumonia: spectrum of parenchymal CT findings. Radiology. 1990;175:711–4.

    PubMed  CAS  Google Scholar 

  92. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007;13:1–7.

    Article  PubMed  Google Scholar 

  93. Tasaka S, Tokuda H, Sakai F, Fujii T, Tateda K, Johkoh T, et al. Comparison of clinical and radiological features of Pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med. 2010;49:273–81.

    Article  PubMed  Google Scholar 

  94. Hardak E, Brook O, Yigla M. Radiological features of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without AIDS. Lung. 2010;188:159–63.

    Article  PubMed  Google Scholar 

  95. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Centers for Disease Control and Prevention (CDC), National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–207.

    Google Scholar 

  96. Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009;41:862–8.

    Article  PubMed  CAS  Google Scholar 

  97. Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother. 2009;64:1282–90.

    Article  PubMed  CAS  Google Scholar 

  98. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004;48:4301–5.

    Article  PubMed  CAS  Google Scholar 

  99. Huang L, Cattamanchi A, Davis JL, den Boon S, Kovacs J, Masur H, et al. International HIV-associated Opportunistic Pneumonias (IHOP) Study; Lung HIV Study. HIV-associated Pneumocystis pneumonia. Proc Am Thorac Soc. 2011;8:294–300.

    Article  PubMed  Google Scholar 

  100. Briel M, Boscacci R, Furrer H, Bucher HC. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis. 2005;5:101.

    Article  PubMed  CAS  Google Scholar 

  101. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215–24.

    Article  PubMed  CAS  Google Scholar 

  102. Moon SM, Kim T, Sung H, Kim MN, Kim SH, Lee SO, et al. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother. 2011;55:4613–8.

    Article  PubMed  CAS  Google Scholar 

  103. Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F, Brochard L, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670–2.

    Article  PubMed  CAS  Google Scholar 

  104. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. MMWR Recomm Rep 2000;49(RR-10):25–26.

    Google Scholar 

  105. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77:299–311.

    Article  PubMed  Google Scholar 

  106. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transpl. 2009;9:S227–33.

    Article  Google Scholar 

  107. Sepkowitz KA. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc. 1996;71:102–3.

    Article  PubMed  CAS  Google Scholar 

  108. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV. 7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transpl. 2002;17:36–9.

    Google Scholar 

  109. Goto N, Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis. 2011;13:551–8.

    Article  PubMed  CAS  Google Scholar 

  110. Thomas S, Vivancos R, Corless C, Wood G, Beeching NJ, Beadsworth MB. Increasing frequency of Pneumocystis jirovecii pneumonia in renal transplant recipients in the United Kingdom: clonal variability, clusters, and geographic location. Clin Infect Dis. 2011;53:307–8.

    Article  PubMed  Google Scholar 

  111. Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum. 2011;41:497–502.

    Article  PubMed  Google Scholar 

  112. Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi. 1999;73:1123–9.

    PubMed  CAS  Google Scholar 

  113. Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther. 2009;11:253.

    Article  PubMed  CAS  Google Scholar 

  114. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D’Cruz D, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46:1615–6.

    Article  PubMed  CAS  Google Scholar 

  115. Thomas CF, Limper AH. Treatment and prevention of Pneumocystis carinii (P. jirovecii) pneumonia in non-HIV-infected patients. http://www.uptodate.com/contents/. Accessed 20 Feb 2012.

  116. Anand S, Samaniego M, Kaul DR. Pneumocystis jirovecii pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis. Transpl Infect Dis. 2011;13:570–4.

    Article  PubMed  CAS  Google Scholar 

  117. Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, Matsushima A, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis. 2011;11:76.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Sadatomo Tasaka

  2. Department of Respiratory Medicine, Social Insurance Central General Hospital, 3-22-1 Hyakunin-cho, Shinjuku-ku, Tokyo, 169-0073, Japan

    Hitoshi Tokuda

Authors
  1. Sadatomo Tasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hitoshi Tokuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sadatomo Tasaka.

About this article

Cite this article

Tasaka, S., Tokuda, H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 18, 793–806 (2012). https://doi.org/10.1007/s10156-012-0453-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-012-0453-0

Keywords

Search

Navigation